Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《China Pharmaceuticals》 2018-18
Add to Favorite Get Latest Update

Clinical Evaluation on Atorvastatin in the Treatment of Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Fibrosis

Chen Qingxian;Wu Haidi;Li Dingfu;Western Central Hospital of Hainan;  
Objective To investigate the clinical value of atorvastatin in the treatment of chronic obstructive pulmonary disease( COPD)complicated with pulmonary fibrosis. Methods Totally 184 patients with COPD complicated with pulmonary fibrosis admitted to our hospital from May 2012 to May 2016 were selected and divided into the control group and the observation group according to the random number table method,92 cases in each group. The patients in the control group were given conventional treatment,on this basis,the patients in the observation group were given Atorvastatin Calcium Tablets. The two groups were treated for 8 weeks. Results After treatment,the levels of FEV_1,FVC,PaO_2,TGF-β_1 and CTGF in the observation group were significantly higher than those in the control group( P 0. 05),while the levels of Pa CO2,hs-CRP,TNF-α and IL-6 in the observation group were significantly lower than those in the control group( P 0. 05). There was no significant difference in the incidence rate of adverse reactions between the two groups( 7. 61% vs. 6. 52%,P 0. 05). Conclusion Atorvastatin can effectively improve the blood oxygen content of patients with COPD complicated with pulmonary fibrosis,improve the respiratory function,reduce the inflammatory response,and improve the quality of life of patients.
【CateGory Index】: R563.9
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved